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Abstract
Introduction: The aim was to examine the effect of a sedative or analgesic
supplement to periprostatic nerve blockage (PNB) on pain reduction during probe
insertion and needle penetration in patients undergoing transrectal ultrasound
(TRUS)-guided prostate biopsy. We also investigated the effects of this procedure
on the positive response rate in re-biopsy.
Material and methods: One hundred TRUS-guided prostate biopsy patients due
to prostate-specific antigen (PSA) levels higher than 2.5 ng/ml and/or abnormal
rectal examination findings were evaluated. Group 1 (PNB) was given
periprostatic lidocaine injection before the procedure. Group 2 (analgesic) was
given tramadol and PNB. Group 3 (sedative) was given midazolam and PNB.
Group 4 (control) was not given any anaesthesia or analgesics. Pain scores were
assessed during probe insertion and needle penetration by a visual analogue
scale.
Results: During probe insertion, the mean pain score of the sedative group was
lower than that of the control, analgesic and PNB groups (p < 0.001, p = 0.009,
and p < 0.001, respectively). During needle penetration, the mean pain score of
the control group was higher than that of the other groups (p < 0.001). The rate
of positive response to re-biopsy was found to be 56% in the control group and
between 92% and 100% in the other three groups (p < 0.001).
Conclusion: According to our results, it can be concluded that midazolam, given
supplementary to PNB, contributes as an effective and safe alternative for pain
control during both probe insertion and penetration of the biopsy needle into
the prostate capsule; however, tramadol supplement does not provide any
additional contributions.
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Introduction
Transrectal ultrasound-guided biopsy (TRUS-Bx) has become a standard
method for early diagnosis of prostate cancer [1]. Previously, the process
was supposed to be painless or cause a feeling of slight discomfort; thus,
it was performed without any analgesia or anaesthesia [1-3]. In subsequent
studies 65% or 90% of men were reported to have pain increasing from
mild discomfort to severe pain [4]. Furthermore, approximately 20% of
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without any analgesia or anaesthesia [4-6].
Additionally, urologists have reported frequent
anxiety in anticipation of prostate biopsy. Patients
with maximum anxiety have been found to be
vulnerable to high levels of pain [7]. Although
numerous studies have revealed the efficacy of
periprostatic nerve blockade (PNB) for prostate
biopsy in achieving pain reduction, there have been
only a limited number of effect and control-related
studies on anal discomfort due to probe insertion
[8-10]. 
Consequently, we performed a randomized,
prospective, controlled, double blind study to
investigate whether a sedative or an analgesic
supplement to PNB would reduce the sensation of
discomfort associated with probe insertion, whether
prostate needle penetration-associated pain would
be controlled more effectively, and how the patients
requiring a re-biopsy would be affected. 
Material and methods
Our study population comprised 100 patients
who were admitted to our clinic between February
2008 and June 2009. Patients with prostate-specific
antigen (PSA) above the level of 2.5 ng/ml and/or
with abnormal digital rectal examination (DRE)
findings were included in the study. Patients who
underwent a previous TRUS-Bx; had active rectal
problems such as haemorrhoids, anal fissure or
stricture; had neurological pathologies; were allergic
to one of the drugs used in the study; had
hemorrhagic diathesis; or had a disease requiring
the treatment of chronic pain were excluded from
the study. Patients in the study group were
assessed by a consultant anaesthetist for suitability
for sedation and were divided into 4 groups using
computer-generated random numbers. All patients
and the physician performing the final evaluation
were unaware of which method of pain
management procedure was used. Local ethical
committee permission and written patient
information and consent forms were collected
before the initiation of the study.
Group 1 (PNB group, n = 25) patients received
periprostatic injection of 10 ml lidocaine 10 min
before the procedure; Group 2 (analgesic group, 
n = 25) patients received per os tramadol
hydrochloride in a dose of 50 mg 45 min and
periprostatic injection of 10 ml lidocaine 10 min
before the procedure; Group 3 (sedative group, 
n = 25) patients received intramuscular injection of
0.05 mg/kg midazolam 30 min and periprostatic
injection of 10 ml lidocaine 10 min before the
procedure; Group 4 (control group, n = 25) was
composed of patients receiving periprostatic
administration of 10 ml 0.9% serum physiologic.
Lubricant was used in the process of probe
insertion in all patients. 
The medication was stopped for patients using
anticoagulants or aspirin a week before the process.
500 mg of oral ciprofloxacin as a prophylaxis was
initiated a night before and on the morning of the
biopsy and continued for 3 days. Patients were
assigned to receive fleet enema for bowel
preparation on the morning of the process. All
patients had DRE before the biopsy. First they were
placed in a left lateral decubitus position, then
prostate glands were examined in sagittal and
transverse planes using a biplanar 7.5 MHz
transrectal ultrasonography probe (Aloka Co, Tokyo,
Japan). In the meantime morphological assessment
of the prostate was performed and the volume of
the prostate was determined automatically with
ultrasonography equipment. PNB was achieved by
the bilateral injection of 10 ml of 2% lidocaine via
a 22-gauge 20 cm Chiba needle at the apex and the
junction between the prostate and seminal vesicles.
The injection site was confirmed by TRUS
monitoring when the prostate and seminal vesicles
were monitored diverging from the rectal wall. For
biopsy an 18-gauge 25 cm Tru-cut biopsy needle
was used (Marflow AG, 8134 Adliswil, and Zurich,
Switzerland). A total of 10-core biopsies were taken:
3 cores from each peripheral zone and 2 from each
far lateral zone. Moreover, additional biopsy cores
were taken from sonographically hypoechoic or
suspected sites in the DRE. 
After the process, the patients were given
a questionnaire to rate their pain between scores
0 and 10 using a visual analogue scale (VAS). They
were asked to assess the level of pain during probe
insertion and needle passage into the prostate
gland. Furthermore, all patients were asked
whether they would accept a second biopsy if
necessary. Ten days later patients were asked to fill
in a form about side effects such as haematuria,
rectal bleeding, vasovagal reaction, urinary infection
and retention.
Statistical data analysis was performed using
SPSS 11.5 for Windows Statistical Software Package.
Continuous variables were analysed for almost
normal distribution using the Shapiro-Wilk test.
Statistical results were presented as follows: mean
± standard deviation for age; PSA, prostate volume,
PSA density, number of biopsies and VAS levels as
median (minimum-maximum). Nominal variables
were presented as the number of subjects and
percentages (%). The importance of age-related
differences between groups was assessed using
one-way analysis of variance. The presence of
statistical differences with respect to PSA, prostate
volume, PSA density, number of biopsies and VAS
levels between groups was analysed using the
Kruskal-Wallis test. Nominal variables were
assessed via Pearson’s chi-square or Fisher’s exactArch Med Sci 5, October / 2010 789
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probability test. The results were considered
significant for p < 0.05. 
Results
No statistically significant difference was found
with respect to mean age between groups, PSA
level, prostate volume, PSA density, abnormal DRE
findings and mean number of biopsy cores taken
(Table I). 
There was a significant difference between the
groups regarding pain during probe insertion 
(p = 0.016, χ2 = 10.280). Group 3 had significantly
lower mean pain scores than Groups 1, 2 and 
4 (Table II). Conversely, Group 1 and Group 2 were
not statistically different from the control group (Group
4) regarding pain during probe insertion (Group 1 ~
Group 4, p = 0.476 and Group 2 ~ Group 4, 
p = 0.846). 
There was a significant difference between
groups regarding pain while inserting the needle
into the prostate gland (p < 0.001, χ2 = 34.139). In
this respect, mean pain score for Group 4 was
significantly higher than for Groups 1, 2 and 
3 (Table III). Statistically, Groups 1, 2 and 3 had lower
pain levels than Group 4 (p < 0.001). Furthermore,
Group 3 had a lower pain level than Group 1 
(p = 0.039). On the other hand, there was no
difference between Groups 3 and 2 (p = 0.125) and
Groups 2 and 1 (p = 0.568) with respect to pain
during the needle passage into the prostate gland.
When assessed with respect to the rate of
positive replies to the question “Would you agree
to another prostate biopsy if it was considered
necessary?”, the rate of positive answers was
higher among patients in Groups 1, 2 and 3 than
that of the control group (Table IV). No significant
difference was found between Group 1 and Groups
2-3 (p = 1.00 and p = 1.00, respectively) and
between Group 2 and Group 3 (p = 0.490).
When biopsy-related side effects were compared
in our study, the groups were found to be similar
(Table V). Conversely, light sedation observed in the
sedative group required hospital stay for no
patients. No drug-related cardiac or respiratory side
effects were observed among patients. 
Discussion 
In the present study we found that midazolam
supplement to PNB during TRUS-Bx reduced anal
discomfort in the course of probe insertion more
than application of only PNB or tramadol
supplement to PNB. Moreover, we found that
sensation of pain was apparently lessening during
needle passage into the prostate gland via PNB.
Additional medication of midazolam had significant
contributions in contrast to ineffective tramadol
addition.
Two major factors are responsible for pain during
prostate biopsy: anal discomfort due to the
ultrasound probe and the development of pain due
to the needle penetrating the prostatic capsule and
originating from the autonomic nerve fibres
innervating the prostatic capsule or the stroma [7,
11, 12]. Also, there may be a relationship between
pain and strong mediators such as cytokines,
prostaglandins and leukotrienes after TRUS-Bx [12].
Numerous authors have believed that transrectal
probe insertion is an important component of pain
during prostate biopsy and nerve blockade will not
reduce pain [13, 14]. To prevent pain during insertion
of the ultrasound probe, the use of topical 
local anaesthetics, non-steroid anti-inflammatory
or centrally acting analgesics and sedative
anaesthetics was investigated before the process
[8, 15, 16]. In a recent study by Raber et al.
administration of lidocaine and prilocaine gel was
reported to decrease pain and anal discomfort
during probe insertion [17]. However, the effect of
this procedure in reduction of pain development
during needle insertion has been controversial [17-
19]. Pain during probe insertion has not been
investigated in studies performed with midazolam
[20, 21]. When assessed regarding pain sensation
during probe insertion, the sedative group achieved
statistically more effective pain control during probe
insertion in our study. We consider that the
sedative, anxiolytic and myorelaxing properties of
midazolam have been effectual. Contrary to our
expectations, we were unable to observe
a statistical difference, although pain sensation
during probe insertion in the analgesic group was
lower than the mean pain scores of the PNB and
Parameter Group 1 (n = 25) Group 2 (n = 25) Group 3 (n = 25) Group 4 (n = 25) p
Age [years] 65.0 ±7.6 66.6 ±8.1 64.6 ±7.9 66.1 ±5.7 0.762
PSA [ng/ml] 9.9 (3.4-41.3) 8.5 (2.5-150.0) 9.3 (3.7-63.0) 9.4 (3.5-84.0) 0.608
Prostate volume [ml] 42.7 (20-100) 40.0 (20-72) 38.6 (20-86.8) 50.0 (18.3-120) 0.179
PSA density 0.24 (0.01-1.76) 0.22 (0.06-3.07) 0.23 (0.11-1.91) 0.17 (0.07-1.76) 0.699
Abnormal DRE 4 (16.0%) 3 (12.0%) 4 (16.0%) 3 (12.0%) 0.954
Biopsy cores (n) 11 (9-12) 11 (10-12) 12 (9-12) 10 (9-12) 0.122
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control groups. We believe that the prevalent
anxiety observed in patients during surgical
intervention has contributed to levels of pain or
discomfort emerging in the sphincter region during
probe insertion and tramadol is not sufficiently
active since it does not exhibit an anxiolytic effect. 
Various methods and drugs have been used for
pain control during needle passage into the
prostate gland [7, 8, 15, 16, 22]. The effectiveness
of transrectal periprostatic lidocaine injection has
been reported in various studies [8, 22]. The PNB
group provided statistically better pain control than
the control group during needle passage through
the prostate gland in our study. Nash et al. formerly
described PNB as an effective and reliable method
[20]. Our results have confirmed the description of
Nash et al. We also observed in our study that the
combination of midazolam + PNB statistically
reduced pain during needle passage into the
prostate compared to the control and PNB groups.
These results are parallel to the results obtained
by Peters et al. and Turgut et al., who used
midazolam in their studies [20, 21]. On the other
hand, our results revealed that PNB + tramadol
administration lessened pain statistically
significantly more than the control group during
needle passage into the prostate gland; however,
the difference with respect to mean pain score was
not statistically significant in general, although the
mean pain score was observed to be lower in
comparison with the PNB group. According to us,
this insignificant result was not possibly due to an
insufficient analgesic effect of tramadol, but
because of a very effective local anaesthetic effect
of PNB. The reports have been conflicting on
tramadol use for controlling the pain emerging
during needle passage into the prostate gland.
Bozlu et al. reported that tramadol application had
no analgesic benefit during biopsy. Hirsh et al.
found that tramadol provided effective and reliable
analgesia in their study where they compared
rectal administration of lidocaine ointment before
the process with the combination of lidocaine
ointment and per oral tramadol [19, 23].
Consequently, we also believe that lidocaine gel
and ointment + tramadol combination can be more
effective with respect to avoidance of the invasive
effect of injection during PNB.
In a study, patients requiring re-biopsy were
reported to be reluctant to undergo a second
intervention due to disagreeable memories of the
first trial [24]. The proportion of patients accepting
re-biopsy suggestions was observed to be
significantly higher than the control group in all
groups. Pain during probe insertion in PNB was not
statistically different from that of the control group.
However, a lot of patients in the PNB group
responded positively for re-biopsy, suggesting that
the main pain deterrent was the pain during needle
penetration. We observed that the sedative group
accepted re-biopsy statistically more than the
control group. We consider that midazolam + PNB
Group Median Pain Score p
1 (n = 25) 4 (2-7) < 0.001
2 (n = 25) 3 (0-8) 0.009
3 (n = 25) 2 (0-5)
4 (n = 25) 4 (2-6) < 0.001
Table II. Pain during probe insertion, comparison with
group 3
Group Median Pain Score p
1 (n = 25) 2 (0-6) < 0.001
2 (n = 25) 1 (0-6) < 0.001
3 (n = 25) 1 (0-5) < 0.001
4 (n = 25) 6 (3-8)
Table III. Pain during needle passage into the prostate
gland
GroupY es, N (%) No, N (%) p
1 (n = 25) 24 (96) 1 (4) < 0.001
2 (n = 25) 23 (92) 2 (8) 0.004
3 (n = 25) 25 (100) 0 (0) < 0.001
4 (n = 25) 14 (56) 11 (44)
Total 87 (87) 14 (14)
Table IV. Acceptance of a re-biopsy. Comparison
between control and other groups
GroupH aematuria Rectal  bleeding  Urinary retention  Urinary infection  Vasovagal reaction 
n/% n/% n/% n/% n/%
1 (n = 25) 8/32% 6/24%  1/4% 3/12%  1/4% 
2 (n = 25) 10/40% 5/20%  3/12% 5/20%  3/12% 
3 (n = 25) 9/36% 7/28%  2/8%  4/16% 2/8%
4 (n = 25) 6/24% 6/24% 1/4%  5/20% 1/4% 
Total 33 24 7 19 7
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provided very active pain control as well as the
anterograde amnestic effect of midazolam,
providing a positive contribution. 
The morbidity and complications of TRUS-Bx are
well known [5, 25]. Sepsis is the most serious
potential complication and the application of
prophylactic antibiotic treatment reduces the risk
successfully [26]. More common but minor
complications are also well documented and the
patient can be informed about the possible
complications. Haematuria has taken the first rank
among the most frequently observed side effects,
with a rate of 33% in our study. This complication
has been reported at between 12.5% and 58.4% in
various studies [5, 27-29]. In addition, we did not
observe any cardiological or respiratory side effects
during the administration of local anaesthetics and
sedation. We consider that midazolam administered
premedication dose and local anaesthetics are
within the confidence interval. The follow-up of vital
findings should be routinely performed by
a physician in the group [20, 21]. Other limitations
of midazolam use were restriction of motor
activities of patients, such as driving, and the
necessity of a companion [20, 21].
In conclusion, according to our data we can state
that PNB is an effective and reliable method in
controlling pain during passage of the biopsy needle
into the prostate capsule. Supplementary
midazolam provides an additional contribution as
an effective, safe and reliable alternative means of
pain control during both probe insertion and
penetration of the biopsy needle into the prostate
capsule. However, we found that unlike midazolam,
supplementary tramadol does not provide an extra
contribution. On the other hand, discomfort
experienced during probe insertion is an important
problem caused by the biopsy procedure.
Nevertheless, we can assert that pain during
penetration of the biopsy needle into the prostate
capsule is the actual deterrent factor when re-
biopsy is necessary.
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